1Barrass B JR, Thurairaja R, Persad RA.More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer. BJU Int,2004,93:1175 -1176.
2Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy:recommendations for diagnosis and therapies. Cancer,2004,100: 892-899.
3Higano CS. Understanding treatments for bone and bone metastases in patients with prostate cancer: a practical review and guide for the cli- nician. Urol Clin North Am,2004,31:331-352.
4Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol,2003,21:392-398.
5Roodman GD. Mechanism of bone metastasis. N Engl J Med, 2004,15:1655-1664.
6Gilbert SM, Olsson CA, Benson MC, et al. The role of intravenous zoledronic acid in the treatment of high-risk prostate cancer. Cur Opin Urol,2003 ,13 :133-135.
7Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res,2002,62:6538-6544.
8Koupparis A, Ramsden A, Persad C. Cognitive effects of hormonal treatment for prostate cancer. BJU Int,2004,93:915-916.
8Zhan L,Quality of life:Conceptual issues[J].J Adv Nurse,1992,17(7):795-800.
9Fawzy FT,Kemeny ME,Fawzy NW,et al.A structurecl psychiatric intervention for cancer patients I Changes over time in methods of coping and affective distyrbance[J]Arth Gen Psychintry,1990,47(8):720-725.
